Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li>Feluda, the paper strip test for COVID-19 diagnosis is set to be launched in Delhi today, according to a report. </li><li>Spain approves phase three trials of Johnson &amp; Johnson COVID-19 vaccine.</li><li>Pfizer’s COVID-19 vaccine is 95% effective, final study shows</li><li>Early trials show that Chinese COVID vaccine, CoronaVac triggers a quick immune response</li></ul>The latest wave of COVID-19 infections across the world has taken the global tally of cases over the 56 million mark. Deaths in the US have surpassed 2,50,000, a new grim milestone amid an unabated resurgence in the worst hit country in the world, according to Johns Hopkins University. India stands second with over 89 lakh cases. There has been a glimmer of hope with three global vaccine candidates showing over 90% efficacy rate in the last one week. Here’s a look at COVID-19 vaccine updates from around the world — Spain approves phase three trials of Johnson &amp; Johnson COVID-19 vaccine Spain has authorised phase 3 trials of the vaccine being developed by Johnson and Johnson-owned Janssen Pharmaceutica, <a href="https://in.reuters.com/article/us-health-coronavirus-vaccine-spain/spain-authorises-phase-iii-trial-of-johnson-johnson-covid-19-vaccine-idINKBN27Y16V">Reuters </a>reported. This is the first vaccine candidate which will enter phase 3 trials in the country and will be conducted in nine hospitals. Feluda paper strip test to be launched in Delhi Feluda, the paper strip test for COVID-19 diagnosis is set to be launched in India’s national capital, Delhi, today, according to a report by <a href="https://www.hindustantimes.com/india-news/feluda-test-kit-set-to-hit-the-market-on-thursday/story-r9MpXIgENV4s3auJAEySMK.html">Hindustan Times.</a> The indigenously developed testing kit based on a gene editing technology called CRISPR was launched by the Tata Group earlier this month. Reports suggest that this paper strip test is expected to be cheaper than the current RT-PCR test. The <keyword id="9073143" type="UNKNOWN" weightage="20" keywordseo="feluda-test">Feluda test</keyword> had shown 96% sensitivity and 98% specificity in tests; and was approved for use by the Indian Council of Medical Research in September. Pfizer’s COVID-19 vaccine is 95% effective, final study shows Global drug makers Pfizer and BioNTech said that their COVID-19 vaccine was found 95 per cent effective in the final analysis of the Phase 3 trial, including in people aged over 65 years, paving the way for the companies to apply for emergency authorisation from US regulators within days. Early trials show that Chinese COVID vaccine, CoronaVac triggers a quick immune response Preliminary trial results show that Sinovac Biotech’s COVID-19 vaccine CoronaVac triggers a quick immune response in healthy volunteers aged 18 to 59 years. According to the findings of the phase 1/2 randomised clinical trial, the vaccine candidate could induce an antibody response in participants within 28 days of the first immunisation, by giving two doses 14 days apart. However the level of antibodies produced was lower than in people who recovered from the disease, <a href="https://in.reuters.com/article/us-health-coronavirus-sinovac/sinovacs-covid-19-vaccine-induces-quick-immune-response-study-idUSKBN27X354">Reuters </a>reported. The research that was published in a Lancet study shows that the vaccine is safe and could provide sufficient protection. Russian President: Sputnik V vaccine could be produced in India and China Russian President Vladimir Putin called for a joint effort by the BRICS countries on the development of the coronavirus vaccines as he suggested that Russia's Sputnik V vaccine against COVID-19 could be produced in China and India, which are members of the five-nation bloc. "We believe it is important to speed up the establishment of the centre for development and research of BRICS vaccines, which we agreed to do two years ago, upon the initiative of our South African friends," Putin said while addressing the 12th BRICS summit via videoconferencing. Moderna’s COVID-19 vaccine shows over 94% efficacy, Indian government is in talks with the US biotech giant India is in dialogue with the US-based biotech giant Moderna over the progress in the clinical trials of its coronavirus vaccine candidate, which the firm said has shown 94.5 percent efficacy, official sources said on Monday. "We are in dialogue not only with Moderna, but also with Pfizer, Serum Institute, Bharat Biotech and Zydus Cadila over the progress of the clinical trials of each of the vaccine candidates and where their vaccines stand in terms safety, immunogenicity and efficacy, and regulatory approvals," a source said. On Monday, <a href="https://www.businessinsider.in/science/health/news/moderna-says-its-coronavirus-vaccine-is-94-5-effective-against-covid-19-a-crucial-victory-in-the-fight-against-the-pandemic/articleshow/79247349.cms">Moderna </a>said that its vaccine candidate against COVID-19 was found to have an efficacy of 94.5 percent. Bharat Biotech begins phase III trials for Covaxin Vaccine maker <a href="https://www.businessinsider.in/india/news/indias-first-vaccine-candidate-covaxins-phase-3-trials-begin/articleshow/79249854.cms">Bharat Biotech</a> has started Phase III trials of Covaxin, India's first indigenous vaccine for COVID-19. The Phase III trials, which involve 26,000 volunteers across India, are being conducted in partnership with the Indian Council of Medical Research (ICMR). According to a <a href="https://in.reuters.com/article/health-coronavirus-india-vaccine/exclusive-india-made-covid-19-vaccine-could-be-launched-as-early-as-february-government-scientist-idINKBN27L0WU">Reuters report</a>, Bharat Biotech COVAXIN could be launched as early as February as studies have so far shown it is safe and effective. Bharat Biotech had earlier hoped to launch it only in the second quarter of next year. SEE ALSO:<a href="https://www.businessinsider.in/stock-market/news/dow-tumbles-345-points-as-fresh-lockdown-measures-overshadow-vaccine-progress/articleshow/79292917.cms" data-type="tilCustomLink"> Dow tumbles 345 points as fresh lockdown measures overshadow vaccine progress</a> <a href="https://www.businessinsider.in/science/health/news/pfizers-new-covid-19-vaccine-is-95-effective-and-the-only-severe-side-effect-to-worry-about-is-fatigue-according-to-the-final-results/articleshow/79284286.cms" data-type="tilCustomLink">Pfizer's new COVID-19 vaccine is 95% effective and the only severe side-effect to worry about is fatigue, according to the final results</a>

COVID-19 vaccine latest updates: Spain approves phase III trials of J&J vaccine, Feluda test kit for COVID to be launched in Delhi

<ul><li>At 7:40 am, the SGX Nifty was down 0.19%, indicating a subdued start for Nifty50.</li><li>Here's a list of stocks to watch for in trade today. </li><li><a href="https://www.businessinsider.in/">Check out the latest news and updates on Business Insider.</a> </li></ul>Indian stock-market indices are likely to open flat on Friday, led by mixed cues from the global peers. At 7:40 am, the SGX Nifty was down 0.19%, indicating a subdued start for Nifty50. However, on Thursday, the US stocks ended in positive territory as fresh stimulus hopes buoyed investor sentiment towards the end of a session. The Dow Jones Industrial Average closed 45 points higher, and the S&amp;P 500 was up 0.39%. These are the stocks to watch out for during the trading session today: Reliance Industries Billionaire Mukesh Ambani's Reliance Industries said it had completed the sale of about 10% stake in its retail unit to a clutch of foreign investors for ₹47,265 crore. Since September 25, the company has sold 10.09% stake in Reliance Retail Ventures (RRVL) to private equity firms Silver Lake Partners, KKR, GIC, TPG and General Atlantic, as well as sovereign wealth funds, Mubadala, ADIA and PIF. The shares of Reliance Industries ended 0.76% lower on Thursday. Vodafone-Idea Post the completion of the much-delayed merger of Bharti Infratel and Indus Towers on Thursday, Vodafone Idea (VIL) received cash consideration of ₹3,760.1 crore for its 11.15% shareholding in Indus. The shares of Vodafone-Idea ended flat on Thursday. Infosys The Infosys subsidiary, Simplus has collaborated with Salesforce for a vaccine management cloud solution. The solution has been built on the Salesforce Platform in support of Salesforce Work.com for Vaccines as the COVID-19 pandemic continues. The shares of Infosys ended 1.22% lower on Thursday. Mphasis IT firm Mphasis subsidiary, Mphasis Consulting, has acquired UK-based Datalytyx for up to £13.3 million (about ₹130.4 crore). The acquisition is expected to provide access to strengthen Mphasis next-generation Data GTM Strategy and provide higher value partnership status with Snowflake and Talend for cloud-based data services, a regulatory filing said. The shares of Mphasis ended 0.50% lower on Thursday. Syngene International Syngene International announced that it had signed an agreement with Deerfield Discovery and Development Corporation (3DC) to collaborate for five years to advance therapeutic discovery projects. The shares of Syngene International ended 0.86% lower on Thursday. Muthoot Finance and Manappuram Finance The Reserve Bank of India (RBI) imposed penalties of ₹10 lakh and ₹5 lakh on Muthoot Finance and Manappuram Finance respectively for norm violations. The central bank has penalised Muthoot Finance for non-compliance with directions issued by RBI on maintenance of loan-to-value ratio in gold loans and on obtaining a copy of PAN card of the borrower while granting gold loans in excess of ₹5 lakh, contravening RBI norms. Manappuram Finance has been fined for non-compliance with directions issued by RBI on verification of ownership of gold jewellery The shares of Muthoot Finance ended 1% lower on Thursday, whereas Manappuram Finance lost nearly 2%. South Indian Bank South Indian Bank announced that the Marginal Cost of Funds Based Lending Rates (MCLR) for multiple tenors had been revised from November 20. One-month MCLR at 7.95% and one-year MCLR at 8.2%. The shares of South Indian Bank ended 4.14% lower on Thursday. Aarti Industries HDFC Mutual Fund reduced its stake in Aarti Industries from 7.08% to 5.08% on November 17. The shares of Aarti Industries ended 0.31% higher on Thursday. Apollo Hospitals Apollo Hospitals and Tata Medical and Diagnostics (TataMD) have collaborated to introduce TataMD CHECK diagnostic test (Feluda) for COVID-19 in India. Apollo Hospitals along with its subsidiary Apollo Diagnostics will offer the Tata MD CHECK testing in the national capital region (NCR) from the first week of December and thereafter it will be rolled out across all major metros in the country. The shares of Apollo Hospitals ended 0.84% higher on Thursday. Emami The Indian FMCG major Emami forayed into the homecare segment with its latest offering - EMASOL - a complete range for home hygiene products. The shares of Emami ended 0.42% lower on Thursday. Route Mobile Route Mobile announced that the chairman and non-executive director of the company, Chandrakant Gupta has resigned from the position of chairmanship of the board. Sandip Kumar Gupta will replace Chandrakant Gupta as the chairman of Route Mobile. The shares of Route Mobile ended 2% higher on Thursday. Zee Learn L&amp;T Infra Finance has increased its stake by 1.26 crore shares via off-market transfer from security trustee &amp; appropriated against outstanding loan amounts on November 18. L&amp;T Finance and L&amp;T Infra Finance now hold nearly 7% stake in the company. The shares of Zee Learn ended 1% lower on Thursday. Gland Pharma Gland Pharma stocks to debut on the bourses today. SEE ALSO: <a href="https://www.businessinsider.in/policy/foreign-policy/news/the-first-meeting-between-india-and-luxembourg-in-20-years-results-in-three-new-bilateral-agreements/articleshow/79305642.cms" data-type="tilCustomLink">The first meeting between India and Luxembourg in 20 years results in three new bilateral agreements</a> <a href="https://www.businessinsider.in/stock-market/news/gland-pharma-shares-demand-is-rising-in-the-grey-market-ahead-of-its-listing-tomorrow/articleshow/79302810.cms" data-type="tilCustomLink">Gland Pharma’s grey market premium rises ahead of listing today</a>

Top stocks to watch — RIL, Infosys, Vodafone-Idea, Apollo Hospitals, Emami, Route Mobile, Syngene, and others

You Searched For "feluda test" and got 2 results

COVID-19 vaccine latest updates: Spain approves phase III trials of J&J vaccine, Feluda test kit for COVID to be launched in Delhi

BI India Bureau

Top stocks to watch — RIL, Infosys, Vodafone-Idea, Apollo Hospitals, Emami, Route Mobile, Syngene, and others

Navdeep Yadav

Popular Keywords

Buying Guides